UK-headquartered biotechnology company Allergy Therapeutics plc (AIM: AGY) on Wednesday announced encouraging interim results from its Phase I/IIa VLP Peanut PROTECT trial, showcasing significant immunological benefits in peanut-allergic patients.

Interim analysis of the first two patient cohorts revealed a dose-dependent reduction in skin sensitivity, with treated patients showing a 48% decrease in wheal size during skin-prick tests compared to an 8% reduction in placebo. VLP Peanut also demonstrated a reduction in allergic biomarkers, including inhibition of Ara h2 IgE binding and decreased basophil reactivity, alongside the induction of protective IgG antibodies.

This trial marks the first evidence of a nanoparticle-based immunotherapy eliciting both immune system activation and allergic response suppression in peanut-allergic patients. With no significant safety signals observed, the study continues into Part B, a double-blind, placebo-controlled phase involving up to 36 patients at US clinical sites.

Allergy Therapeutics specialises in allergy immunotherapies and aims to transform allergic disorder treatments through innovative solutions like VLP Peanut.